Navigation Links
Silence Therapeutics Additional Listing
Date:12/20/2011

LONDON, December 20, 2011 /PRNewswire/ --

Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") a leading global RNA interference (RNAi) therapeutics company, today announces that application has been sought for 530,000 new ordinary shares of 1 pence each ("Ordinary Shares") to be admitted to trading on AIM. The new Ordinary Shares are being issued in accordance with a contractual agreement with Dr. Philip Haworth, former Chief Executive Officer of Silence.

It is expected that dealings in the new Ordinary Shares, which will rank pari passu in all respects with the existing issued share capital of the Company, will commence on 21 December 2011.

Notes for editors

About Silence Therapeutics plc (http://www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. Silence offers one of the most comprehensive short interfering RNA (siRNA) therapeutic platforms available today based on a strong intellectual property portfolio and large clinical safety database. Silence's clinical siRNA product pipeline is one of the broadest in the industry.

The Company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX™, DACC and DBTC. AtuPLEX enables the broad functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. The DACC delivery system allows functional delivery of siRNA molecules selectively to the lung endo-thelium with a long duration of target mRNA and protein knock-down. The DBTC delivery system enables functional delivery of siRNA molecules selectively to liver cells including hepatocytes.

Additionally, the Company has a platform of novel siRNA molecules based around its AtuRNAi chemical modification technology, which provides a number of advantages over conventional siRNA molecules. Silence's unique RNAi assets also include structural features for RNAi molecules and specific design rules for increased potency and reduced off-target effects of siRNA sequences.

The Company's lead internal drug candidate is Atu027, a liposomal formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutic candidates in the area of oncology. Atu027 incorporates two of the Company's technologies, AtuRNAi and AtuPLEX™. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as repeated, intravenous administration. Encouraging interim safety and pharmacokinetic data were presented at the American Society of Clinical Oncology Annual Meeting in June 2011. The study is expected to be completed in the first half of 2012.

The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer/Quark, and Novartis/Quark. Silence is actively pursuing the establishment of additional partnerships. Silence Therapeutics has operations in both Berlin and London.

For further information, please contact:

Silence Therapeutics
Thomas Christély/Max Herrmann
+49-30-9489-2800/+44-20-7491-6520
t.christely@silence-therapeutics.com
m.herrmann@silence-therapeutics.com

M:Communications (Europe)
Peter Laing / Emma Thompson / Claire Dickinson
+44-20-7920-2345 / +44-20-7920-2342
healthcare@mcomgroup.com

Singer Capital Markets
Shaun Dobson/Claes Spång
+44-20-3205-7500
shaun.dobson@singercm.com
claes.spang@singercm.com    



'/>"/>
SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
2. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
3. Silence Therapeutics Appoints New Vice President of Research
4. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
5. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
6. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
7. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
8. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
9. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
10. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
11. Silence Therapeutics Provides Corporate and Development Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... 2017 , ... Proscia Inc. , a data solutions ... whole slide imaging solutions, are hosting a pre-conference workshop at the Digital ... Best-in-Class Strategy for Digital Pathology,” will feature Proscia CEO, David West Jr., and ...
(Date:9/20/2017)... ... 2017 , ... RoviSys, a leading independent provider of comprehensive ... an office in Taipei, Taiwan. This new location allows RoviSys to better support ... in the region. Located in the Neihu area of Taipei, the office allows ...
(Date:9/19/2017)... , ... September 19, 2017 , ... VetStem Biopharma ’s CEO and founder, Dr. ... PhD in Riordan’s new book "Stem Cell Therapy: A Rising Tide". Dr. Harman and ... They bonded over an interest in the potential of stem cell therapy and a ...
(Date:9/19/2017)... ... September 19, 2017 , ... Avomeen Analytical Services, ... of its 2017 Science Student Award. The scholarship program is dedicated to helping ... service defray the costs of obtaining their science education. , Avomeen began the ...
Breaking Biology Technology:
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
Breaking Biology News(10 mins):